OR WAIT null SECS
May 12, 2023
Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.
May 08, 2023
These models are useful in predicting whether an unknown substance of abuse can permeate the BBB to produce effects predicted by the Public Health Assessment via Structural Evaluation (PHASE) approach.
May 02, 2023
In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.
March 17, 2023
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
March 03, 2023
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
February 21, 2023
In this episode, Ana Ladino provides an update on the acceptance of a novel excipient onto CDER’s pilot program.
January 16, 2023
The members reviewed the measures to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.
December 12, 2022
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
November 03, 2022
Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.
October 18, 2022
In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.